Y-mAbs Therapeutics, Inc.
YMAB · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -6.6% | -21.1% | 43.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 86.4% | 85.6% | 70.4% | 87.8% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -28.7% | -24.5% | -22% | -45.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -16.6% | -24.9% | -25.6% | -37.9% |
| EPS Diluted | -0.072 | -0.12 | -0.15 | -0.16 |
| % Growth | 40.4% | 20% | 6.3% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | $0 | $0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |